Original Research
Accepted on 27 Feb 2026
Efficacy and safety of zanubrutinib and camrelizumab combined with CD19 chimeric antigen receptor T-cell in the treatment of relapsed/refractory diffuse large B-cell lymphoma
in Cancer Immunity and Immunotherapy